With this new appointment, Oz will advise PanTheryx on strategies to expand its impact on health and wellness through its leading technology position and focus on colostrum science.
Oz brings decades of medical, nutrition, wellness, and communications expertise to the PanTheryx board.
As former vice-chair and professor of surgery at Columbia University Medical Center, Oz is a world-renowned practicing cardiothoracic surgeon who has authored over 400 original publications, articles, and medical books.
He is also the host of the Emmy award-winning television series The Dr. Oz Show, as well as co-founder of HealthCorps, a national nonprofit with a mission to educate and improve physical and mental health in American teens.
PanTheryx was founded in 2007 to create nutritional solutions for pediatric infectious diarrhea, the second leading killer of children under the age of five in the developing world.
Capitalising upon the great potential of its patented technology platform, PanTheryx has evolved to leverage the cellular and biomolecular processes of bovine colostrum to develop and commercialize a wide range of nutritional interventions and first-in-class therapeutics.
Colostrum is rich in immunoglobulins, antimicrobial peptides, growth factors, cytokines and oligosaccharidesm, all of which can be targeted to produce specific therapeutic activity through PanTheryx's platform.
Oz joins other recent additions to the PanTheryx board including Dr. Rajiv Shah, MD, president of the Rockefeller Foundation, and Dr. Thomas Bumol, PhD, executive director of the Allen Institute for Immunology.
PanTheryx is a biotechnology company committed to realising the potential of bovine colostrum based therapies to address a range of health conditions.
The company commercializes first-in-class therapeutics, with products developed from its patented technology platform spanning the range of nutritional interventions to biologics.
Founded in 2007, PanTheryx is headquartered in Boulder, Colorado and has production facilities in Phoenix, AZ and Ripon, CA. Its flagship product, DiaResQ, is available in over 30,000 pharmacies and retail stores in the US.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer